Medacta Group (SWX:MOVE) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

MOVE Panoramica delle azioni

Medacta Group SA sviluppa, produce e distribuisce dispositivi medici ortopedici e neurochirurgici in Europa, Nord America, Asia-Pacifico e a livello internazionale.

Informazioni sull'azienda

MOVE analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	3/6
Prestazioni passate	3/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 19.97% all'anno

Gli utili sono cresciuti del 2.4% nell'ultimo anno

Analisi del rischio

Ha un alto livello di debito

Medacta Group SA Concorrenti

Sonova Holding

SWX:SOON

CHF 17.4b

Metall Zug

SWX:METN

CHF 564.8m

Straumann Holding

SWX:STMN

CHF 20.1b

Ypsomed Holding

SWX:YPSN

CHF 5.6b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Medacta Group
Prezzi storici delle azioni
Prezzo attuale dell'azione	CHF 129.80
Massimo di 52 settimane	CHF 135.00
Minimo di 52 settimane	CHF 98.10
Beta	1.16
1Variazione di 1 mese	7.27%
Variazione a 3 mesi	6.05%
Variazione di 1 anno	7.45%
3Variazione a 3 anni	-6.35%
Variazione a 5 anni	59.26%
Variazione dall'IPO	35.07%

Notizie e aggiornamenti recenti

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Aug 06

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Jun 20

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Apr 17

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Mar 29

Recent updates

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Aug 06

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Jun 20

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Oct 17

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Sep 29

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Aug 11

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Jul 27

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

Jul 03

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Apr 28

Is Medacta Group (VTX:MOVE) A Risky Investment?

Apr 08

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dec 25

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Dec 09

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Nov 09

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

Sep 16

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Aug 20

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Jul 02

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

May 28

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

May 12

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Mar 31

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Mar 17

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Feb 07

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Dec 10

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Nov 05

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Sep 30

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Aug 26

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Jul 20

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

May 19

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Apr 05

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Mar 02

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

Feb 02

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Jan 12

Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Dec 21

Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

Dec 03

Rendimenti per gli azionisti

	MOVE	CH Medical Equipment	CH Mercato
7D	3.7%	5.2%	2.6%
1Y	7.5%	9.7%	8.8%

Ritorno vs Industria: MOVE ha avuto una performance inferiore rispetto al Swiss Medical Equipment che ha registrato un rendimento 11.3 % nell'ultimo anno.

Rendimento vs Mercato: MOVE ha avuto una performance inferiore al mercato Swiss che ha registrato un rendimento 9.2 % nell'ultimo anno.

Volatilità dei prezzi

Is MOVE's price volatile compared to industry and market?
MOVE volatility
MOVE Average Weekly Movement	3.2%
Medical Equipment Industry Average Movement	3.9%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	1.7%

Prezzo delle azioni stabile: MOVE non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di MOVE è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1958	1,696	Francesco Siccardi	www.medacta.com

Medacta Group SA sviluppa, produce e distribuisce dispositivi medici ortopedici e neurochirurgici in Europa, Nord America, Asia-Pacifico e a livello internazionale. Offre strumenti di pianificazione 3D personalizzati per l'utilizzo in procedure di anca, ginocchio, spalla, sostituzione articolare, medicina sportiva e colonna vertebrale. Medacta Group SA è stata fondata nel 1958 e ha sede a Castel San Pietro, in Svizzera.

Medacta Group SA Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Medacta Group con la sua capitalizzazione di mercato?
MOVE statistiche fondamentali
Capitalizzazione di mercato	CHF 2.59b
Guadagni(TTM)	CHF 45.05m
Ricavi(TTM)	CHF 485.85m

57.4x

Rapporto P/E

5.3x

Rapporto P/S

MOVE è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
MOVE Conto economico (TTM)
Ricavi	€510.78m
Costo del fatturato	€162.93m
Profitto lordo	€347.85m
Altre spese	€300.49m
Guadagni	€47.36m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

Sep 25, 2024

Utile per azione (EPS)	2.38
Margine lordo	68.10%
Margine di profitto netto	9.27%
Rapporto debito/patrimonio netto	49.4%

Come si è comportato MOVE nel lungo periodo?

Vedi performance storica e confronto

Dividendi

0.4%

Rendimento attuale del dividendo

25%

Rapporto di remunerazione

MOVE Panoramica delle azioni

Premi

Analisi del rischio

Medacta Group SA Concorrenti

SWX:SOON

CHF 17.4b

SWX:METN

CHF 564.8m

SWX:STMN

CHF 20.1b

SWX:YPSN

CHF 5.6b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Now 20% undervalued after recent price drop

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Recent updates

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Now 20% undervalued after recent price drop

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dividend of CHF0.55 announced

Full year 2023 earnings: EPS and revenues miss analyst expectations

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Insufficient new directors

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Medacta Group SA to Report Q4, 2023 Results on Feb 02, 2024

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

First half 2023 earnings released: EPS: €1.46 (vs €1.28 in 1H 2022)

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Upcoming dividend of CHF0.54 per share at 0.5% yield

Is Medacta Group (VTX:MOVE) A Risky Investment?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Medacta Group SA to Report Fiscal Year 2022 Results on Feb 03, 2023

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Medacta Group SA to Report Q2, 2023 Results on Sep 22, 2023

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

First half 2022 earnings released: EPS: €1.28 (vs €1.49 in 1H 2021)

Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Medacta Group SA Provides Revenue Guidance for the Year 2022

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group SA Approves Distribution

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Consensus forecasts updated

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Full year 2021 earnings: EPS misses analyst expectations

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Medacta Launches 360° (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS €1.49 (vs €0.48 in 1H 2020)

Medacta Group SA Confirms Revenue Guidance for the Year 2021

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Medacta Announces Successful Completion of First Reverse Shoulder Arthroplasties Using NextAR Augmented Reality Surgical Platform

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

Medacta Announces First U.S. Surgery with the New M.U.S.T. Lt System in Minimally Invasive Spine Surgery

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Full year 2020 earnings released: EPS €1.86 (vs €0.59 in FY 2019)

Medacta Announces the Launch of MySpine for S2-Alar-Iliac Fixation and Further Enhances its MySolutions Personalized Ecosystem